share_log
  • Headlines
  • Tevogen Bio Signs Letter Of Intent With CD8 Technology To Build Up To A $50M R&D And Manufacturing Facility; No Impact On Shareholder Equity

Tevogen Bio Signs Letter Of Intent With CD8 Technology To Build Up To A $50M R&D And Manufacturing Facility; No Impact On Shareholder Equity

Benzinga ·  Oct 30 00:45
  • CD8 Technology Services, LLC ("CD8 Technology") to provide turn-key facility for Tevogen Bio
  • Reinforces Tevogen Bio's commitment to preserving shareholder value
  • Expected to further enhance Tevogen Bio's ambitious growth agenda

WARREN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, took significant steps toward expanding R&D and manufacturing capabilities.

The proposed facility is intended to support both pre-clinical research and GMP manufacturing capabilities, staffed by Tevogen.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated